105,814 research outputs found

    G. Tortora; Dizionario giuridico italiano-francese, francese-italiano

    No full text
    G. Tortora; Dizionario giuridico italiano-francese, francese-italiano. In: Revue internationale de droit comparé. Vol. 43 N°4, Octobre-décembre 1991. pp. 956-958

    G. Tortora; Dizionario giuridico italiano-francese, francese-italiano

    No full text
    G. Tortora; Dizionario giuridico italiano-francese, francese-italiano. In: Revue internationale de droit comparé. Vol. 43 N°4, Octobre-décembre 1991. pp. 956-958

    TORTORA observations of GRB 080319B

    No full text
    We present results of TORTORA wide-field camera optical observations of GRB 080319B, performed before, during and after the gamma event with high time resolution

    High-Speed and Wide-Field Photometry with TORTORA

    No full text
    The facilities of the instrument TORTORA having a time resolution of 1/7 of second and a field of view of 18x25 degrees are presente

    The High-Speed and Wide-Field TORTORA Camera: description and results

    No full text
    The instrument TORTORA with a time resolution of 0.13 sec and a field of view of 16x20 degrees is described. Its results on GRB 080319B are presente

    High-Speed and Wide-Field Photometry with TORTORA

    No full text
    We present the photometric analysis of the extended sky fields observed by the TORTORA optical monitoring system. The technology involved in the TORTORA camera is based on the use of a fast TV-CCD matrix with an image intensifier. This approach can both significantly reduce the readout noise and shorten the focal length following to monitor relatively large sky regions with high temporal resolution and adequate detection limit. The performance of the system has been tested using the relative magnitudes of standard stars by means of long image sequences collected at different airmasses and at various intensities of the moon illumination. As expected from the previous laboratory measurements, artifact sources are negligible and do not affect the photometric results. The following analysis is based on a large sample of images acquired by the TORTORA instrument since July 2006

    Type II regulatory subunit of protein kinase restores cAMP-dependent transcription in a cAMP-unresponsive cell line.

    No full text
    cAMP-dependent protein kinase appears to play a role in cAMP-induced gene expression in mammalian cells. There exist two major types of cAMP-dependent protein kinase, type I and type II, which are distinguished by their regulatory subunits, RI and RII, respectively. We investigated the role of type I and type II protein kinase in the cAMP-induced gene expression by either stable or co-transfection of RI alpha, RII alpha, or RII beta gene in an expression vector together with somatostatin-chloramphenicol acetyltransferase (SS-CAT) fusion gene using a cAMP-unresponsive mutant pheochromocytoma cell line (A126-1B2). Introduction of the RII beta gene restored the capability of these cells to induce the SS-CAT gene expression in response to forskolin stimulus and induced a changed morphology which resembled that of wild type. The RII alpha gene also induced SS-CAT gene expression but to a lesser degree than that achieved by the RII beta gene, whereas the RI alpha gene had no effect. The induction of SS-CAT gene expression by the RII beta gene was specifically blocked by the 21-mer RII beta antisense oligodeoxynucleotide. These results show for the first time that type II but not type I regulatory subunit of cAMP-dependent protein kinase is essential for a cAMP-induced gene transcription

    Antisense strategies targeting protein kinase C: preclinical and clinical development

    No full text
    Altered protein kinase C-alpha (PKC-alpha) expression has been implicated in tumor promotion and carcinogenesis. One potentially attractive therapeutic intervention may be the use of selective antisense oligonucleotides to inhibit production of PKC-alpha. In preclinical studies, the antisense oligonucleotide LY900003 (ISIS 3521;Affinitak; Isis Pharmaceuticals, Carlsbad, CA) has shown selective inhibition of PKC-alpha mRNA and protein expression and has shown antitumor activity. In clinical studies, LY900003 has shown activity as a single agent, but the most promising data have been obtained in combination with chemotherapy, particularly in patients with non-small cell lung cancer. Data from phase I and II studies have led to ongoing randomized phase III trials in combination with either cisplatin and gemcitabine or carboplatin and paclitaxel. Studies in other tumor types will also investigate the benefit of combining LY900003 with conventional chemotherapy
    corecore